- Facing pharmacy trends for the remainder of the year
- Study: Type 2 diabetes market competition heats up amid disease rate increase
- Three new Takeda diabetes drugs become available
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Hamacher's Dave Wendland to moderate DSN Diabetes & Chronic Care Roundtable for 10th-consecutive year
BETHESDA, Md. Revenues for drug maker Spherix fell in second quarter 2010 and for the first six months of the year, according to financial data released this week.
Spherix, which develops drugs for diabetes and metabolic disorders, reported second-quarter revenues of $327,139, compared with $332,241 in second quarter 2009. Revenues for the first six months of 2010 were $659,430, compared with $692,911 last year. That translated into a net loss of $2.56 million for the quarter and $4.7 million for the first half of the year.
Spherix also announced plans to release efficacy results from a late-stage clinical trial of its D-tagatose compound in patients with Type 2 diabetes in mid-September, and is looking for a drug company to be its development partner. The company also is investigating the drug, which it acquired from the University of Kentucky Research Foundation, as a treatment for high triglycerides.